Drug Discovery World

SEPTEMBER 5, 2024

Biotechnology company SeaBeLife has secured orphan drug designation (ODD) from the European Medicines Agency (EMA) for its drug candidate SBL01 in the treatment of acute liver failure (ALF). The committee considered that this constitutes a clinically relevant advantage.”

Small Molecule 147

Small Molecule Drugs Production Regulations 147

Drug Discovery World

JUNE 26, 2024

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. SPG302 is a once-a-day pill being developed as a regenerative treatment for neurodegenerative and neuropsychiatric diseases.

Small Molecule 189

Small Molecule Pharmacokinetics Drugs Clinical Trials 189

Drug Discovery World

AUGUST 8, 2023

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer.

Small Molecule 246

Small Molecule Drugs Licensing Licensing 246

Drug Discovery World

APRIL 19, 2023

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. New treatments aim to take advantage in cancer cells’ DNA repair mechanisms. Image: Human breast cancer cells stained for DNA (red).

Small Molecule 246

Small Molecule DNA Drugs Laboratories 246

Drug Discovery World

JANUARY 11, 2024

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW). .”

Drug Trials 246

Drug Trials Trials Small Molecule Clinical Trials 246

Drug Discovery World

AUGUST 16, 2024

Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Diana Spencer, Senior Digital Content Editor, DDW The post New data support antitumour drug misetionamide in ovarian cancers appeared first on Drug Discovery World (DDW).

Small Molecule 147

Small Molecule Drugs Clinical Trials Therapies 147

Drug Discovery World

FEBRUARY 8, 2023

EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function. The drug was granted orphan drug designation by the FDA in May 2021.

FDA 130

FDA Treatment Small Molecule Disease 130

Drug Discovery World

MAY 26, 2023

AM1476, a highly selective small molecule, delivered as an orally administered tablet, was found to be safe and well-tolerated at all relevant doses in a trial of approximately 100 healthy subjects. There are currently no treatments on the market that effectively reverse scarring.

Treatment 130

Treatment Small Molecule Trials Disease 130

Drug Discovery World

JULY 19, 2024

LT-HSCs are vital for bone marrow transplants as they can replenish the blood cells after treatment for blood cancers. This means that we rely on non-human, animal models to test drugs that can have effects on blood cell production and in targeting blood diseases (such as leukaemias).

Small Molecule 130

Small Molecule Drugs Engineering Disease 130

Covalent Modifiers

FEBRUARY 6, 2024

Fibroblast growth factor receptor (FGFR) kinase inhibitors have been shown to be effective in the treatment of intrahepatic cholangiocarcinoma and other advanced solid tumors harboring FGFR2 alterations, but the toxicity of these drugs frequently leads to dose reduction or interruption of treatment such that maximum efficacy cannot be achieved.

Small Molecule 86

Small Molecule Treatment Science Therapies 86

Drug Discovery World

JULY 18, 2024

The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML). The drug is intended for patients with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m).

Small Molecule 130

Small Molecule FDA Drugs Therapies 130

Drug Discovery World

MARCH 15, 2024

The top stories: New drug shows promising neuroprotective effects Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD). million raised to progress Parkinson’s treatment Mission Therapeutics has raised £25.2 ($32.1)

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Discovery World

APRIL 8, 2024

Cedric Ververken, CEO of Confo Therapeutics, commented: “Receiving this additional VLAIO grant will strengthen our existing small molecule and antibody discovery efforts on high-value Class B GPCRs, which further paves the way to unlock new treatments for a range of endocrine and metabolic indications including obesity.

Disease 130

Disease Small Molecule Drugs Treatment 130

Drug Target Review

OCTOBER 11, 2023

Most of these conditions are genetic in origin and the majority have no effective treatment. One of our drug candidates at Samara activates Transient Receptor Potential Mucolipin 1 (TRPLM1), a protein that’s at the centre of the degradative machinery that’s so key to autophagy.

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

Drug Discovery World

MAY 30, 2024

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”

Small Molecule 147

Small Molecule Treatment International Production 147

Drug Discovery World

AUGUST 27, 2024

“There is clearly a need for alternative mechanisms of action that can provide physicians and patients with improved overall health outcomes in the pursuit of weight loss beyond those achieved with GLP-1 and GIP drugs. Assessing psychiatric effects of CB1 inhibition The clinical trial will enrol 120 patients across four treatment groups.

Trials 130

Trials Small Molecule Clinical Trials Treatment 130

Drug Discovery World

AUGUST 19, 2024

The study will assess the safety, pharmacokinetic and pharmacodynamic profiles and anti-tumour activity for CV6-168 in the treatment of patients with advanced metastatic solid tumours refractory to standard treatment, including colon, gastric, breast, ovarian, lung, and other solid tumours.

Trials 147

Trials Therapies DNA Small Molecule 147

Drug Discovery World

AUGUST 28, 2024

JT: We are developing novel small molecule, disease-modifying, allosteric regulators to treat serious diseases such as Parkinson’s disease and other dementias. Gain’s lead drug candidate GT-02287 is a best-in-class small molecule for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases.

Research 162

Research Small Molecule Disease Therapies 162

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

SEPTEMBER 4, 2024

EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the side effects observed with other therapies.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. In addition to STC-15 and our METTL1, our pipeline contains a number of preclinical programs that are advancing rapidly for the treatment of viruses, neurodegeneration, cancer, and immuno-inflammatory conditions.

Therapies 162

Therapies Small Molecule RNA DNA 162

The Pharma Data

JULY 28, 2021

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits. Yancopoulos, M.D.,

Small Molecule 52

Small Molecule Research Science Disease 52

DrugBank

JULY 24, 2024

In the constantly evolving field of drug discovery, the term “undruggable” refers to proteins and targets in the body that, until recently, were considered impossible to treat with traditional drugs. This is a game-changer, especially in the fight against cancer and other complex diseases.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

OCTOBER 20, 2022

This is the latest episode of the free DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. In the first article, he talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.

Small Molecule 130

Small Molecule Pharmaceuticals Drugs Science 130

Collaborative Drug

AUGUST 29, 2023

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.

Small Molecule 82

Small Molecule Treatment Disease Research 82

Drug Hunter

AUGUST 15, 2023

LRRK2 has been a hotly pursued drug target for Parkinson’s Disease based on human genetics. On Sunday, it was disclosed that additional, likely on-target adverse findings were observed in a primate GLP study on long-term treatment with Merck’s second-generation LRRK2 inhibitors. appeared first on Drug Hunter. already a member?

Small Molecule 229

Small Molecule Trials Treatment Disease 229

Drug Discovery World

FEBRUARY 12, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

JANUARY 12, 2023

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination. . The post Pheno Therapeutics buys rights to potential remyelination drug appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Licensing Licensing Drugs 130

Drug Discovery World

DECEMBER 7, 2023

Inipharm has initiated Phase I dosing of its lead candidate, INI-822, which is a small-molecule inhibitor for HSD17B13, a gene implicated in nonalcoholic steatohepatitis (NASH). This is the first example of an OOC provider’s data supporting clinical progression of a drug for metabolic, fibrotic liver disease.

Disease 147

Disease Small Molecule Drugs Treatment 147

Drug Discovery World

AUGUST 18, 2023

My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future.

Small Molecule 130

Small Molecule Virus Drugs Clinical Research 130

Drug Discovery World

MARCH 12, 2024

RA: Biomia is developing drug candidates for pain, addiction and mental health conditions. What are some of the historical challenges with these drugs? RA: What advantages does a plant-based approach bring to drug development? RA: What opportunity is there for better treatments in pain and mental health conditions?

Small Molecule 147

Small Molecule Synthetic Chemistry Production Molecular Biology 147

Drug Discovery World

OCTOBER 20, 2022

This is the latest episode of the free DDW podcast, “What does the changing drug discovery and development landscape mean for the future?”. In the first article, he talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.

Small Molecule 130

Small Molecule Drugs Pharmaceuticals Science 130

The Pharma Data

JANUARY 19, 2021

Precision medicine developer Kura Oncology is positioned to make a meaningful difference in the treatment of cancer in the next few years with its two, wholly-owned, small molecule compounds. Kura Oncology CEO Troy Wilson pictured above. Photo courtesy of Kura. dependent HNSCC.

Small Molecule 52

Small Molecule Therapies FDA Approval Trials 52

Drug Discovery World

MARCH 15, 2023

Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer. The study shows how a breakthrough drug called CADD522 blocks a gene associated with driving the cancer’s spread in mice implanted with human bone cancer.

Small Molecule 130

Small Molecule Medical Schools Drugs Clinical Trials 130